おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Xpect Vision Technology
company
About
Xpect Vision Technology is a high-tech company committed to disruptive and innovative technology development.
- 11 - 50
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- ¥150M
- Industries
- Health Care,Image Recognition,Medical Device
- Founded date
- Jan 1, 2015
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Founded in 2015, XpectVision Technology is a high-tech company committed to disruptive and innovative technology development. XpectVision has been trailblazing in the field of photon-counting X-ray imaging. Also the company is poised to be the leader of other futuristic imaging technology, including high-speed high-definition imaging chip.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
¥180M
Xpect Vision Technology has raised a total of
¥180M
in funding over 2 rounds. Their latest funding was raised on
Dec 17, 2021 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 17, 2021 | Series C | — | 1 | — | — | Detail |
| Jul 21, 2020 | Series B | ¥150M | 1 | — | — | Detail |
| Jun 27, 2016 | Series A | ¥30M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
3
Xpect Vision Technology is funded by 3 investors.
Guoxin Zhuoyue Venture Capital
and CCB Healthcare Industry Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series C |
|
|
— | Series B |
Zhongjin Qianhai Development Fund
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
